Reframing Sjögren’s Disease: Patient perspectives and clinical context in a systemic and often progressive disease

Windermere Y | Developed and offered by Novartis Pharmaceuticals Corporation

Program Description

During this program, we will explore the serious and often progressive nature of Sjögren’s disease in order to recognize the significant disease burden that patients face. We will also show how the sicca plus framework can help identify patients with Sjögren’s disease who may benefit from biologic therapy. Finally, we will take a closer look at the critical role B cells play in the disease.

Speaker

Presenter: Latisha Heinlen, MD, PhD
Rheumatology Associates of Oklahoma
CEO & Medical Director
Oklahoma City, Oklahoma